Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/214368
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMayén, Ana Lucía-
dc.contributor.authorSabra, Mirna-
dc.contributor.authorAglago, Elom K.-
dc.contributor.authorPerlemuter, Gabriel-
dc.contributor.authorVoican, Cosmin-
dc.contributor.authorRamos, Inés-
dc.contributor.authorDebras, Charlotte-
dc.contributor.authorBlanco, Jessica-
dc.contributor.authorViallon, Vivian-
dc.contributor.authorFerrari, Pietro-
dc.contributor.authorOlsen, Anja-
dc.contributor.authorTjønneland, Anne-
dc.contributor.authorLangmann, Fie-
dc.contributor.authorDahm, Christina C.-
dc.contributor.authorRothwell, Joseph-
dc.contributor.authorLaouali, Nasser-
dc.contributor.authorMarques, Chloé-
dc.contributor.authorSchulze, Matthias B.-
dc.contributor.authorKatzke, Verena-
dc.contributor.authorKaaks, Rudolf-
dc.contributor.authorPalli, Domenico-
dc.contributor.authorMacciotta, Alessandra-
dc.contributor.authorPanico, Salvatore-
dc.contributor.authorTumino, Rosario-
dc.contributor.authorAgnoli, Claudia-
dc.contributor.authorFarràs, Marta-
dc.contributor.authorMolina Montes, Esther-
dc.contributor.authorAmiano, Pilar-
dc.contributor.authorChirlaque, María Dolores-
dc.contributor.authorCastilla, Jesús-
dc.contributor.authorWerner, Mårten-
dc.contributor.authorBodén, Stina-
dc.contributor.authorHeath, Alicia K.-
dc.contributor.authorTsilidis, Kostas-
dc.contributor.authorAune, Dagfinn-
dc.contributor.authorWeiderpass, Elisabete-
dc.contributor.authorFreisling, Heinz-
dc.contributor.authorGunter, Marc J.-
dc.contributor.authorJenab, Mazda-
dc.date.accessioned2024-07-05T11:49:19Z-
dc.date.available2024-07-05T11:49:19Z-
dc.date.issued2024-06-03-
dc.identifier.issn1741-7015-
dc.identifier.urihttps://hdl.handle.net/2445/214368-
dc.description.abstractBackground Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MetS) are implicated in the aetiology of non-communicable diseases. Our study aimed to evaluate associations between NAFLD and MetS with overall and cause-specific mortality. Methods We used dietary, lifestyle, anthropometric and metabolic biomarker data from a random subsample of 15,784 EPIC cohort participants. NAFLD was assessed using the fatty liver index (FLI) and MetS using the revised definition. Indices for metabolic dysfunction-associated fatty liver disease (MAFLD) were calculated. The individual associations of these indices with overall and cause-specific mortality were assessed using multivariable Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (95%CIs). As a subobjective, risk associations with adaptations of new classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic and alcohol-related liver disease (MetALD) were also assessed. Results Among the 15,784 sub-cohort participants, a total of 1997 deaths occurred (835 due to cancer, 520 to CVD, 642 to other causes) over a median 15.6 (IQR, 12.3-17.1) years of follow-up. Compared to an FLI < 30, FLI >= 60 was associated with increased risks of overall mortality (HR = 1.44, 95%CI = 1.27-1.63), and deaths from cancer (HR = 1.32, 95%CI = 1.09-1.60), CVD (HR = 2.06, 95% CI = 1.61-2.63) or other causes (HR = 1.21, 95%CI = 0.97-1.51). Mortality risk associations were also elevated for individuals with MAFLD compared to those without. Individuals with MetS were at increased risk of all mortality endpoints, except cancer-specific mortality. MASLD and MetALD were associated with higher risk of overall mortality. Conclusions Our findings based on a prospective cohort suggest that individuals with hepatic steatosis or metabolic dysfunction have a higher overall and cause-specific mortality risk.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Science and Business Media LLC-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12916-024-03366-3-
dc.relation.ispartofBMC Medicine, 2024, vol. 22, num. 1-
dc.relation.urihttps://doi.org/10.1186/s12916-024-03366-3-
dc.rightscc by (c) Mayén, Ana Lucía et al, 2024-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationMalalties del fetge-
dc.subject.classificationSíndrome metabòlica-
dc.subject.otherLiver diseases-
dc.subject.otherMetabolic syndrome-
dc.titleHepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2024-06-28T08:49:15Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid38825687-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s12916-024-03366-3.pdf814.5 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons